Gram Peptides FDA Warning Letter: Letter 721806

Updated August 23, 2026

Gram Peptides of Rancho Santa Fe, California received FDA warning letter 721806, dated March 31, 2026 and posted to the agency's public index on April 7, 2026. It is one of seven letters issued to research-peptide sellers that day, and its full text is live on FDA's website.

The letter

On March 31, 2026, FDA signed seven warning letters to sellers of research peptides and posted all of them a week later, on April 7. Letter 721806 went to Gram Peptides at a Rancho Santa Fe, California address. By number it sits directly after 721805, the letter to Prime Sciences of Scottsdale — consecutive entries in the same day's batch. Unlike several of its siblings, whose letters this index cites only through FDA's database search, the Gram Peptides letter has a confirmed page of its own on fda.gov, linked under Sources.

What the letters found

Two findings run through the batch. The first concerns language: product pages that describe therapeutic effects — what a compound is said to do in a human subject — printed alongside research-use-only labeling. The second concerns structure: administration supplies offered in the same shopping cart as the compounds. The letters count the second as evidence on its own; the contents of a checkout entered the record without any written claim attached to them.

On the labeling question, the agency's stated position is quoted from the batch: despite research-use-only disclaimers, "evidence obtained from your website establishes that your products are intended to be drugs for human use." What any recipient wrote or changed after receiving its letter is not in the verified record here, and this page makes no claim about it.

Coded names in the batch

Coverage of the seven letters also documents listings under coded designations in place of standard compound names — "GLP-1 SM" and "GLP-3 RT" are the recorded examples. Per the letters, FDA read the coding as circumvention: marketing a recognized drug class while avoiding the words that would name it. The examples are documented at batch level, and this index does not tie them to Gram Peptides or to any other single recipient.

Letter record

Position in the batch

The seven-letter action is recorded in full at FDA warning letters of March 31, 2026, which tabulates every recipient, number, and location. Seven letters in one day exceeded the December 10, 2024 action, which named four sellers of GLP-1-class compounds, and trade coverage has reported more than one hundred FDA warning letters to peptide and research-use-only sellers since September 2025. Gram Peptides also carries an entry in the vendor index, this site's roster of documented entities.

Sources

1. FDA Warning Letter, Gram Peptides, 721806-03312026. fda.gov
2. Policy Canary analysis of the March 31, 2026 batch. policycanary.io
3. Partnership for Safe Medicines, PDF summary of the seven letters (April 7, 2026 posting). safemedicines.org

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.